TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06357104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroencephalogram biofeedback
Description: EB is conducted for 20 minutes per section with two sections per day in the primary efficacy endpoint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical brain stimulation
Description: EBS is conducted for 20 minutes per section per day in the primary efficacy endpoint.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultra-low frequency transcranial magnetic stimulation
Description: ULF-TMS is conducted mainly for the left side of the participant's brain for 20 minutes per section per day in the primary efficacy endpoint.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline Hydrochloride
Description: Sertraline is taken in the morning for 150 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Clonazepam is taken in the morning for 1 mg per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: Alprazolam is introduced near the end of the primary efficacy endpoint for 0.4 mg per night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol is introduced at the secondary efficacy endpoint starting with 47.5 mg per night and increase to 95 mg per night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Olanzapine is taken throughout the trial with 7.5 mg per night at first, and increases to 10 mg per night after the cocktail therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin Sodium 20 MG
Description: Pravastatin sodium is introduced in the secondary efficacy endpoint with 20 mg per night.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril Valsartan Sodium Hydrate
Description: Sacubitril valsartan sodium is introduced in the secondary efficacy endpoint with 100 mg per day.
Study: NCT06570122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 5A's/5R's advice
Description: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health warning leaflet
Description: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health warning leaflet
Description: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-powered chatbot support
Description: Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.
Study: NCT06120322

Intervention type: OTHER
Intervention: Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies
Description: During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected

Intervention type: OTHER
Intervention: Environmental factor monitoring; collection of blood, feces and urine. For UC: collection of 8 additional biopsies
Description: During the routine surveillance according to the normal clinical practice, blood samples, feces and urines will be collected from UC patients and T1D patients (0, 6, and 12 months). Moreover, for UC patients during the surveillance sigmoidoscopy according to the normal clinical practice (or colonoscopy if the patient has more than 8 years; at the enrollment and after 12 months), colonic biopsies will be collected
Study: NCT04915716

Intervention type: OTHER
Intervention: Peripheral blood glucose levels were monitored
Description: Peripheral blood glucose levels were monitored
Study: NCT06348407

Intervention type: DRUG
Intervention: IgE monoclonal antibody
Description: omalizumab
Study: NCT05481463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: surufatinib,250mg, qd, po, 28 days for a cycle
Study: NCT06430112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: After induction of anesthesia, bilateral TAPB was performed under ultrasound guidance. The patients in the bupivacaine liposome group were injected with bupivacaine liposome 133mg(10ml+ 10ml 0.9% normal saline mixed into 20ml)/ point (two points in total).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: Patients in ropivacaine group were given 0.25% ropivacaine 20ml/ point (two points in total).
Study: NCT05349058

Intervention type: DRUG
Intervention: Immune Checkpoint Inhibitors
Description: Patients receive Immune Checkpoint Inhibitor as per oncology protocol
Study: NCT06350058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (low dose)
Description: The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.
Study: NCT05481463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102,35mg/m2, po, d1-5, d8-12, bid, 28 days for a cycle
Study: NCT06350058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (low dose)
Description: The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (low dose)
Description: The protein content of each dose is 2.5 μg. The antigen content shall not be less than 2000U, and each person shall receive one dose of 0.5ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (high dose)
Description: The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (high dose)
Description: The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated rotavirus vaccine (high dose)
Description: The protein content of each dose is 5 μg. The antigen content shall not be less than 4000U, and each person shall receive one dose of 0.5ml.
Study: NCT06178289

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Cavilon Advanced Skin Protectant
Description: 3M Cavilon Advanced Skin Protectant is applied to the study area of partial-thickness wounds (IAD category 2A, peri-wound MASD, peri-stomal MASD). Application of the study device should be according to the manufacturer's IFU. Comprehensive training for nurses will be provided to the study nurses.
Study: NCT04808778

Intervention type: DRUG
Intervention: Hydroxyurea therapy per standard care
Description: Moderate-dose of 20mg/kg/day
Study: NCT05231408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval aerobic exercise training
Description: High-intensity interval aerobic exercise training will be given to training group on treadmill 3 days in a week and 15-45 minutes in a day for 8 weeks with the assistance of a physiotherapist.~The training workload of the active phase of high-intensity interval aerobic exercise training will be applied at 80-100% of peak oxygen consumption or 85-95% of peak heart rate or according to Borg scale dyspnea/fatigue 15-18 points.~The training workload of the active recovery phase of high-intensity interval aerobic exercise training will be applied at 50-60% of peak oxygen consumption or 60-75% of peak heart rate or according to Borg scale dyspnea/fatigue 11-13 points.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Breathing exercises will be given to the control group 120 times in a day and 7 days in a week for 8 weeks as a home program. The control group will be followed-up by telephone once a week.
Study: NCT06350058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Aluminum hydroxide adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Aluminum hydroxide adjuvant.
Study: NCT05429177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY101 ointment or vehicle
Description: QY101 ointment or vehicl topical applied to skin
Study: NCT04853043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered every 2 weeks (14 days). The initial dose of 500 mg/m2 is to be administered by IV infusion over 120 minutes on the first day of the treatment. In the absence of infusion reactions, subsequent doses are to be administered over 60 minutes biweekly. Each cycle will be defined as 14 days of treatment.
Study: NCT06106646

Intervention type: DIETARY_SUPPLEMENT
Intervention: No active intervention in this protocol (previously randomized to Vitamin C)
Description: In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.

Intervention type: OTHER
Intervention: No active intervention in this protocol (previously randomized to Placebo)
Description: In the original VCSIP study, pregnant women were randomized to receive either extra Vitamin C every day (500mg/day) or placebo. This trial is a follow-up trial with no active intervention.
Study: NCT06178289

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard hospital wound treatment protocol
Description: Comparator: Standard hospital wound treatment protocol
Study: NCT05608759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimodal prehabilitation
Description: 4 weeks of an supervised, pre-operative exercise prescription augmented by a wearable fitness device.
Study: NCT06522880

Intervention type: DIAGNOSTIC_TEST
Intervention: CMV PCR on saliva
Description: Observational study to measure prevalence of CMV shedding by saliva PCR
Study: NCT05557903

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Humanized Anti-CD52 Monoclonal Antibody Injection
Description: Single dosing: DLT observation for 7 days after administration; Multiple dosing: 3times/weeks,12 times, 28 days of DLT observation
Study: NCT05203861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Treatment
Description: Sessions 1-7: Pleasurable activities + imaginal recounting and reinforcement of positive mood effects (continued for sessions 8-15) Sessions 8-10: Cognitive exercises focusing on identifying positive aspects of experience, taking responsibility for positive outcomes, and imagining future positive events Sessions 11-14: Exercises to cultivate and savor positive experiences Session 15: Relapse prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Negative Affect Treatment
Description: Sessions 1-7: Exposure therapy to feared or avoided situations, sensations, or memories (continued for sessions 8-15) Sessions 8-10: Cognitive restructuring of probability, cost, and attributional biases Sessions 11-14: Capnometry-assisted respiratory training Session 15: Relapse prevention
Study: NCT06126666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL103
Description: ABL103 will be administered biweekly of every 28-day cycle in the dose-escalation. The dosing interval to be used in tumor-expansion part will be evaluated based on the emerging safety and PK data from the dose-escalation part of the study.
Study: NCT04956575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study: NCT05356936

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (MK-7)
Description: Participants will receive Vitamin K2 (MK-7) daily by mouth.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Participants will receive Vitamin D3 daily by mouth.
Study: NCT06525272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Chymotrypsin(OsrhCT)
Description: Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, 4,000U/vial, freeze-dried powder, 20ml of the prepared drug will be injected into the thoracic cavity through a chest tube.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant Human Chymotrypsin(OsrhCT)
Description: Placebo for Recombinant Human Chymotrypsin (OsrhCT), provided by Wuhan Healthgen Biotechnology Corporation, freeze-dried powder, stored at 2-8°C.
Study: NCT04956575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study: NCT06343740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMET-Y
Description: Competitive memory training (COMET) is a transdiagnostic intervention first developed for adults and later adapted to be used in children and adolescents. The adapted version for youth consists of 7 sessions in which participants learn to facilitate activation of functional/positive thoughts instead of relying on dysfunctional/negative thoughts by using positive self-verbalizations, imagery, body posture, and music. In addition, they are challenged to reformulate dysfunctional/negative thoughts into more functional/positive thoughts. As an addition to the original COMET protocol, there is a parent session in which parents receive psycho-education about their influence on self-esteem. Parents learn to be a 'co-therapist' and to support practicing at home and improve generalization.
Study: NCT04956575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection
Study: NCT05663567

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution oriented approach
Description: Implementing a solution-focused approach to support breastfeeding

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: solution oriented approach
Description: Implementing a solution-focused approach to support breastfeeding
Study: NCT04751565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy
Description: Statistically significant different in terms of Bleeding on Probing will be recorded between groups.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleeding on Probing change reduction following peri-implant mucositis non surgical therapy
Description: Statistically significant different in terms of Bleeding on Probing will be recorded between groups.
Study: NCT06202430

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High Thoracic Erector Spinae Plane Block
Description: High Thoracic-ESPB The patient was placed in the lateral decubitus. The transverse process of T2 was identified. After negative aspiration, hydro dissection using 2 mL of saline was performed. Eventually, 30 mL of the LA bupivacaine 0.25% and epinephrine 5 µg/ mL was injected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Block
Description: Shoulder Block Suprascapular nerve block (SSNB) approach: The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle.~Axillary nerve block technique:~The nerve approach had been described in plane from cranial to caudal. After local infiltration of the skin with 1% lidocaine, the needle tip must be visualized within the fascia below the teres minor muscle and just above the PCHA. After cautious aspiration, 10 ml of 0.5% bupivacaine was injected on the posterior aspect of the humerus.
Study: NCT05316337

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with investigational device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrocardiogram recording
Description: ECG recording with reference device
Study: NCT04956575

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1010
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% sodium chloride solution for injection
Study: NCT05055167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: single agent, 300mg Q3W IH until disease progressed
Study: NCT05912920

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric band
Description: gastric band

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: gastric band
Description: gastric band
Study: NCT04793763

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: traditional therapeutic exercises
Description: group A will receive traditional exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapeutic exercises and McKenize technique
Description: Group B will receive traditional therapeutic exercises and McKenize technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapeutic exercises and deep neck flexor exercises
Description: Group C receive traditional therapeutic exercises and deep neck flexor exercises
Study: NCT05833321

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sarcopenia diagnostic test
Description: measurement of impedance and physical tests (hand grip dynamometer, walking test), SEFI nutritional intake questionnaire
Study: NCT05985382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Body Resistance Exercise
Description: Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
Study: NCT04956575

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 0.5 milliliter (mL) intramuscular (IM) injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: 0.5 milliliter (mL) intramuscular (IM) injection
Study: NCT04756830

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Adsorbed COVID-19 (inactivated) Vaccine
Description: Participants will receive two doses with 14-days interval of adsorbed COVID-19 (inactivated) vaccine
Study: NCT05985382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper Body Resistance Exercise
Description: Participants will complete a leg extension exercise with weight equivalent to 75% of their estimated 1-repetition maximum 3 sets, 10 repetitions.
Study: NCT04740931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab
Description: Faricimab will be administered by intravitreal (IVT) injection as specified in each treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Aflibercept 2 mg will be administered by IVT injection once every 4 weeks (Q4W) from Day 1 through Week 20 (a total of 6 injections).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Procedure
Description: The sham is a procedure that mimics an IVT injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.